Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

GNPX

+ Watchlist+ Portfolio

Genprex, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.67
52-Week Range
$1.63 – $80.96
Market Cap
$2.28M
P/E (TTM)
—
EPS (TTM)
-9.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.15
PEG Ratio
—
Return on Equity
-233.73%
Return on Assets
-99.41%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
4.26
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-9.99M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-13.06M

Market Snapshot

About

Genprex, Inc. is a clinical-stage biopharmaceutical company developing targeted gene therapies for cancer and diabetes. The company's lead oncology candidate Reqorsa is a tumor suppressor gene therapy delivered through a proprietary nanoparticle delivery system for treatment of non-small cell lung cancer. Genprex is also developing Oncoprex immunogene therapy and diabetes treatment GPX-002 using its TUSC2 nanoparticle technology platform. The company's approach focuses on delivering therapeutic genes directly to diseased tissues while minimizing systemic exposure.